WO1992012161A1

WO1992012161A1 - Novel pyrimido-benzothiazines

Info

Publication number: WO1992012161A1
Application number: PCT/US1991/009161
Authority: WO
Inventors: Kaoru Shimada; Yuji Shishido
Original assignee: Pfizer Inc.
Priority date: 1991-01-07
Filing date: 1991-12-16
Publication date: 1992-07-23
Also published as: JPH04230690A; PT99979A; DE69104067T2; ATE111469T1; IE920028A1; FI933102A0; DK0566592T3; DE69104067D1; EP0566592B1; JPH0739422B2; EP0566592A1; ES2059209T3; FI933102A; CA2099558A1; IE64069B1

Abstract

This invention relates to novel pyrimido-benzothiazine derivative compounds. The compounds of the present invention inhibit the action of the lipoxygenase enzyme and are useful in the treatment or alleviation of inflammatory diseases, allergy and cardiovascular diseases in mammals. This invention also relates to pharmaceutical compositions comprising such compounds.

Description

Novel pyrimido-benzothiazines

Technical Field This invention relates to novel pyrimido-benzothiazine derivative compounds. The compounds of the present inven- tion inhibit the action of the lipoxygenase enzyme and are useful in the treatment or alleviation of inflammatory diseases, allergy and cardiovascular diseases in mammals. This invention also relates to pharmaceutical compositions comprising such compounds. Background Art

Arachidonic acid is known to be the biological precur¬ sor of several groups of endogenous metabolites, prosta- glandins including prostacyclins, thromboxanes and leuko- trienes. The first step of arachidonic acid metabolism is the release of arachidonic acid and related unsaturated fatty acids from membrane phospholipids via the action of phospholipase. Free fatty acids are then metabolized either by cyclooxygenase to produce the prostaglandins and throm¬ boxanes or by lipoxygenase to generate hydroperoxy fatty acids which may be further converted to the leukotrienes. Leukotrienes have been implicated in the pathophysiology of inflammatory diseases including rheumatoid arthritis, gout, asthma, ischemia reperfusion injury, psoriasis and inflamma¬ tory bowel disease. Compounds that inhibit lipoxygenase are expected to provide significant new therapy for both acute and chronic inflammatory conditions.

Recently, several review articles on lipoxygenase inhibitors have been reported. See H. Masamune and L. S. Melvin, Sr. , in: Annual Reports in Medicinal Chemis- try 24 (1989) pp. 71-80 (Academic) ; and B. J. Fitzsimmons and J. Rokach in: Leukotrienes and Lipoxyσenases (1989) pp. 427-502 (Elsevier) . Certain derivatives of phenothiazine of the general formula

wherein X is, inter alia. S, SO or S0₂; R^l is, inter alia, H or (C -C alkyl; R², R³, R⁴ and R⁵ are inter alia, independent¬ ly H, (Cj-C₆)alkyl, (C_j-Cg)alkenyl or - (CE₂)__ti where n is 0-6 and M is halogen or various groups and T is H or OR¹⁵ where R¹⁵ is H or various groups are disclosed in EP 138481, published April 24, 1985 and corresponding to JP 60155165, as leukotriene biosynthesis inhibitors useful in treating allergic conditions, asthma, cardiovascular disorders, inflammation and certain skin diseases.

Disclosure of the Invention The present invention provides pyrimido-benzothiazine derivative compounds of the following formulae:

( I ) ( I I )

and the pharmaceutically-acceptable salts thereof, wherein R¹ is hydrogen or (C₁-C₆)alkyl; R² is hydrogen, halogen,

(C^Cg)alkyl, (C^Cg)alkoxy or (C_j-C^halosubstituted alkyl; R³ is hydrogen or (Cj-Cg)alkyl; R⁴ is hydrogen, (Ci-Cg)alkyl, (C₃- C_g)cycloalkyl, (Cj-Cg)

alkyl or aryl-f -Cg)alkyl; provided that in formula (I), R¹, R², R³ and R⁴ are not simultaneously hydrogen, R², R³ and R⁴ are not simultaneously hydrogen when R¹ is methyl and R² and R³ are not simulta¬ neously hydrogen when R¹ and R⁴ are respectively methyl; provided further that in formula (II) , R¹, R² and R³ are not simultaneously hydrogen and R² and R³ are not simultaneously hydrogen when R¹ is methyl; and provided further still that the groups R² and R³ may be attached to any available position on the ring in formula (I) or (II) . A preferred group of compounds comprises compounds of formula (I) wherein R¹ is (Cj-C₆)alkyl. Also preferred are compounds of formula (I) wherein R¹ is methyl and R² is halogen, (Cj-Cg)alkyl or (Cj-Cg)alkoxy. Another preferred group of compounds comprises compounds of formula (II) wherein R¹ is (Cj-Cg)alkyl. Also preferred are compounds of formula (II) wherein R¹ is methyl and R² is halogen, (C_- C₆)alkyl, (Cj-Cg)alkoxy or

alkyl.

In formulae (I) and (II) , above, and throughout this specification and the appendant claims, the term "halogen" is used to mean radicals derived from the elements fluorine, chlorine, bromine and iodine; the term "alkyl" is used to mean straight or branched chain radicals, including, but not limited to, methyl, ethyl, n-propyl, isopropyl, butyl and the like; the term "alkoxy" is used to mean -OR₅ wherein R_j is an alkyl radical, including, but not limited to, methoxy, ethoxy, propoxy, isopropoxy, butoxy and the like; the term "halosubstituted alkyl" refers to an alkyl radical as described above substituted with one or more halogens, including, but not limited to chloromethyl, trifluoromethyl, 2,2,2-trichloroethyl and the like; the term "alkoxyalkyl" is used to mean -RgOR₇ wherein Rg and Ry are respectively alkyl radicals, including, but not limited to methoxymethyl, methoxyethyl, ethoxymethyl, ethoxyethyl and the like; the term "arylalkyl" means an aryl group appended to an alkyl radical including, but not limited to, phenylmethyl- (benzyl) , phenylethyl, 2-phenylethyl, phenylpropyl and 2- pyridylmethyl, and the like; the term "cycloalkyl" is used to mean carbocyσlic radicals, including, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.

Certain of the compounds of the above formula may form acid salts. The pharmaceutically-acceptable acid salts are those formed from acids which yield non-toxic acid salts, for example, hydrochloride, hydrobromide, sulfate or bisulfate, phosphate or acid phosphate, acetate, citrate, fumarate, gluconate, lactate, maleate, succinate, tartrate, methanesulfonate, benzenesulfonate, toluenesulfonate, and formate salts.

This invention includes pharmaceutical compositions for treatment of inflammatory diseases, allergy and cardiovascu¬ lar diseases in a mammal which comprises a pharmaceutically- acceptable carrier or diluent and a compound of the above formula (I) or (II) or a pharmaceutically-acceptable salt thereof.

This invention further includes methods for treating inflammatory diseases, allergy and cardiovascular diseases in a mammal which comprise administering to said mammal an effective amount of a compound of the above formula (I) or

(II) or a pharmaceutically-acceptable salt thereof.

Detailed Description The compounds of formulae (I) and (II) , above, can be prepared by any of a number of synthetic methods. A preferred method is shown in Scheme A and described below wherein R¹, R², R³ and R⁴ are as described above. S c h e m e fl

< I V ) (I)

ant

According to the synthetic method shown in Scheme A, above, bromine is added dropwise to an ice-cooled solution or suspension of a pyrimidine-2,4(lH,3H)-dione derivative of formula (III) in water until the solution or suspension is colored pale yellow. The pyrimidine-2,4(lH,3H)-dione derivatives of formula (III) are prepared, for example, by the methods described in Heterocyclic Compounds 16. The pyrimidine supplement II. D. J. Brown, An Interscience Publication, John Willy & Sons, New York, 1985, Table LVIII, page 728. To the resulting pale yellow solution or suspen- sion is added carefully an ice cold saturated aqueous NaHC0₃ solution. The resulting reaction mixture is refluxed, the solvent is removed and the residue is recrystallized from an appropriate solvent or chromatographed over silica-gel to give a 5-hydroxypyrimidine-2,4(lH,3H)-dione derivative of formula (IV) .

Then, to a solution or suspension of a 5-hydroxy- pyrimidine-2,4(lH,3H)-dione derivative of formula (IV) in a reaction inert solvent is added N-bromosuccinimide portion- wise at room temperature. A preferred solvent is ethanol. The reaction mixture is stirred until the derivative of formula (IV) disappears. Then, a 2-aminobenzenethiol derivative of formula (V) is added and the mixture is heated at reflux. Certain 2-aminobenzenethiol derivatives of formula (V) are commercially available and, further, the derivatives of formula (V) can be prepared from the corre¬ sponding 2-aminobenzothiazoles by hydrolysis as described by Mital, R. L. , et al., J. Chem. Soc. (c) , 2148 (1969). When a precipitate results after reflux of the reaction mixture, the precipitate is collected to give a 1,5-dihydro-2H- pyrimido[4,5-b] [l,4]benzothiazine-2,4(3H)-dione derivative of formula (I) . When no precipitate is obtained after reflux, the derivative of formula (I) is obtained by chromatographic separation on silica gel. The foregoing method for reacting derivatives of formula (IV) with derivatives of formula (V) to yield derivatives of formula (I) is analogous to the method described by Sako, M., et al., Chem. Pharm. Bull., 32, 2474 (1984).

When derivative compounds of formula (II) are desired, a solution or suspension of a l,5~dihydro-2H-pyrimido[4,5- ft>. [l,4]benzothiazine-2,4(3H)-dione derivative of formula (I) wherein R⁴ is hydrogen in acetonitrile is prepared. To that solution or suspension at room temperature is added, dropwise, an oxidant such as diethylazodicarboxylate, 1,4- benzoquinone or 2,3-dichloro-5,6-dicyano-l,4-benzoquinone. Alternatively, oxygen can be used as the oxidant. A preferred oxidant is diethylazodicarboxylate. The reaction mixture is stirred. When a precipitate results, the precipitate is collected and washed with diethylether to give a 2H-pyrimido[4,5-b] [l,4]benzo- thiazine-2,4(3H)-dione derivative of formula (II). When no precipitate is obtained after oxidation, the solvent is removed from the reaction mixture, and the residue is triturated with diethylether and filtered to give a compound of formula (II) .

The pharmaceutically-acceptable salts of the compounds of the present invention are readily prepared by contacting said compounds with a stoichiometric amount of, in the case of non-toxic cation, an appropriate metal hydroxide or alkoxide or amine in either aqueous solution or a suitable organic solvent; or, in the case of a non-toxic acid salt, an appropriate mineral or organic acid in either aqueous solution or a suitable organic solvent. The respective salt may then be obtained by precipitation or by evaporation of the solvent.

The compounds of this invention inhibit the activity of the lipoxygenase enzyme. This inhibition has been demon¬ strated by an assay using rat peritoneal cavity resident cells which determines the effect of said compounds on the metabolism of arachidonic acid as described in Jap. J. Inflammation 7:145-150, 1987, "Synthesis of leukotrienes by peritoneal macrophages".

The ability of the compounds of the present invention to inhibit the lipoxygenase enzyme makes them useful for controlling the symptoms induced by the endogenous metabo¬ lites arising from arachidonic acid in a mammalian subject. The compounds therefore are valuable in the prevention and treatment of disease states in which the accumulation of arachidonic acid metabolites are the causative factor, e.g., allergic bronchial asthma, skin disorders, rheumatoid arthritis, osteoarthritis and thrombosis. Thus, the compounds of formula (I) and (II) , and their pharmaceutically-acceptable salts are of particular use in the treatment or alleviation of inflammatory diseases, allergy and cardiovascular diseases in a human subject as well as in the inhibition of the lipoxygenase enzyme.

For treatment of the various conditions described above, the compounds of this invention and their pharmaceu- tically-acceptable salts can be administered to a human subject either alone, or, preferably, in combination with pharmaceutically-acceptable carriers or diluents in a pharmaceutical composition, according to standard pharmaceu¬ tical practice. A compound of this invention can be administered by a variety of conventional routes of adminis¬ tration including oral and parenteral administration and by inhalation. When the compounds are administered orally, the dose range will be from about 0.1 to 20 mg/kg body weight of the subject to be treated per day, preferably from about 0.1 to 1.0 mg/kg per day in single or divided doses. If parenteral administration is desired, then an effective dose will be from 0.1 to 1.0 mg/kg body weight of the subject to be treated per day. In some instances it may be necessary to use dosages outside these limits, since the dosage will necessarily vary according to the age, weight and response of the individual patient as well as the severity of the patient's symptoms and the potency of the particular compound being administered.

For oral administration, the compounds of the invention and their pharmaceutically-acceptable salts can be adminis¬ tered, for example, in the form of tablets, powders, lozenges, syrups or capsules, or as an aqueous solution or suspension. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch. Further, lubricating agents, such as magnesium stearate, are commonly added. In the case of capsules, useful diluents are lactose and dried corn starch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening and/or flavoring agents can be added. For intramuscular, intraperitoneal, subcutaneous and intravenous use, a sterile solutio of the active ingredient is pre- pared, and the pH of the solutions should be suitably adjusted and buffered. For intravenous use, the total concentration of solutes should be controlled to make the preparation isotonic. The present invention is illustrated by the following examples. However, it should be understood that the invention is not limited to the specific details of these examples. Proton nuclear magnetic resonance spectra (NMR) were measured at 270 MHz unless otherwise indicated and peak positions are expressed in parts per million (ppm) downfield from tetramethylsilane. The peak shapes are denoted as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad.

EXAMPLE 1 3-Propyl-2H-pyrimidof4.5-b^~| r1.41benzothiazine-2.4 (3H)-dione A. 5-Hydroxy-3-propylpyrimidine-2.4 (1H.3H)-dione

To an ice-cooled solution of 3-propylpyrimidine- 2,4(1H,3H)-dione (3.00 g) in H₂0 (100 ml) was added dropwise bromine (1.56 g) until the solution was colored pale yellow. An ice cold saturated NaHC0₃ solution was added carefully to the reaction mixture. The alkalized solution was refluxed for 12 hours. After removal of the solvent, the residue was recrystallized from ethanol to give 5-hydroxy-3-propyl- pyrimidine-2,4(lH,3H)-dione (2.32 g, 70% yield). B. 1.5-Dihvdro-3-propyl-2H-Pyrimidof4.5-b^~| [1.4Ibenzo- thiazine-2,4 (3H)-dione

To a solution of the 5-hydroxy-3-propylpyrimidine- 2,4(lH,3H)-dione (0.85 g) in ethanol (40 ml), N-bromo- succinimide (0.98 g) was added in portions at room tempera- ture. The mixture was stirred for 30 min. 2-Aminobenzene- thiol (0.94 g) was added and the mixture was heated at reflux for one hour. After cooling, the precipitate was collected to give l,5-dihydro-3-propyl-2H-pyrimido[4,5- b][l,4]benzothiazine-2,4(3H)-dione (1.20 g, 87% yield). C. 3-Propyl-2H-pyrimido.4,5-bl n.4.benzothiazine-2.4 (3H_- dione

To a solution of the l,5-dihydro-3-propyl-2H-pyrimido- [4,5-b][l,4]benzothiazine-2,4(3H)-dione (0.55 g) in acetoni- trile (40 ml) was added dropwise diethylazodicarboxylate (0.52 g) at room temperature. The mixture was stirred for two hours. After the solvent was removed, the residue was triturated with diethylether and filtered to give 3-propyl- 2H-pyrimido[4,5-b] [l,4]benzothiazine-2,4(3H)-dione (0.43 g, 78% yield) . .p.: 258°C

IR: (KBr) cπr¹: 2950, 1650 , 1520, 1430

NMR: (DMSO-dg) δ : 8. 16 (1H, dd, 1.5Hz , 8Hz) , 8 . 00

(1H, dd, 1.5HZ , 8Hz) , 7.82 (1H, dt, 1.5Hz , 8Hz) , 7.76 (1H, dt, 1.5Hz, 8Hz) , 3.81 (2H, t, 7.5 Hz) , 1.58 (2H, dt, 7.3Hz, 7.5HZ) , 0.90 (3H, t, 7.5Hz) .

EXAMPLE 2 6-Chloro-l.5-dihydro-3-methyl-2H-pyrimido- f4.5-blT1.4]benzothiazine-2.4 (3H.-dione Employing the procedure of Example 1, parts A and B with 3-methylpyrimidine-2,4(lH,3H)-dione and 2-amino-3- chlorobenzenethiol yielded the title compound, m.p.: 268-270^βC (dec.)

IR^KBrJcπf¹: 3360, 1697, 1638, 1463, 1307, 750 NMR: (DMSO-dg) δ: 3.15 (3H,s) , 6.34 (1H,S), 6.85 (1H, dd, 7.7Hz, 8.1Hz), 7.08 (1H, d, 7.7Hz), 7.26 (1H, d, 8.1HZ), 11.61(1H,S).

EXAMPLE 3 1 _r5-Dihydro-3.8-dimethyl-2H-pyrimidoT4,5-b^~|- f1,4]benzothiazine-2_f4f3H)-dione

Employing the procedure of Example 1, parts A and B with 3-methylpyrimidine-2,4(lH,3H)-dione and 2-amino-5- methylbenzenethiol yielded the title compound, m.p.: 285^βC (dec.) IR:( Br)c -¹: 3320, 2990, 1700, 1620, 1600, 1500, 1310, 815 NMR: (DMSO-dg) δ l 11.30 (IH, s) , 7.40 (IH, s) ,

6.90 (IH, d, 8HZ) 6.78 (IH, d, 8Hz) , 3. 14 (3H, s) , 2. 11 (3H, s) .

EXA PLE 4 1_f5-Dihydro-8-methoxy-3-methyl-2H-pyrimido- r4.5-b.ri.41benzothiazine-2-4.3H_-dione Employing the procedure of Example 1, parts A and B, with 3-methylpyrimidine-2,4(lH,3H)-dione and 2-amino-5- methoxybenzenethiol yielded the title compound. m.p.: 261.4°C

IR: ( Br)cπf¹: 3325, 1700, 1617, 1498, 1305, 1227, 1034, 818, 750

NMR: (DMSO-d₆) δ : 3.14 (3H, s) , 3.64 (3H, s) , 6.60-7.50 (4H, m) , 11.31 (IH, s) . EXAMPLE 5

8-Ethoxy-l _r5-dihydro-3-methyl-2H-pyriιaido.4.5-b1-

[1.41 enzothiazine-2.4(3H)-dione Employing the procedure of Example 1, parts A and B, with 3-methylpyrimidine-2,4(lH,3H)-dione and 2-amino-5- ethoxybenzenethiol yielded the title compound, m.p.: 261°C (dec.)

IR:(KBr)_: 3300, 3200, 1715, 1600, 1495, 1470 NMR: (DMSO-dg) δ : 11.30 (IH, s) , 7.29 (IH, s) , 6.96 (IH, m) , 6.60 (IH, m) , 3.89 (2H, q, 7Hz) , 3.14 (3H, s) , 1.25 (3H, t, 7HZ)

EXAMPLE 6 8-Fluoro-l ,5-dihydro-3-methyl-2H-pyrimido14.5-b^~|- f1.41benzothiazine-2_τ4(3H)-dione Employing the procedure of Example 1, parts A and B, with 3-methylpyrimidine-2,4(lH,3H)-dione and 2-amino-5- fluorobenzenethiol yielded the title compound, m.p.: 280°C (dec.)

IR: (KBr)cm-¹: 3280, 3080, 1717, 1694, 1604, 1496, 1472, 1307, 1250, 1198, 897, 743 NMR: (DMSO-dg) _ : 3.14 (3H, s) , 6.86 (IH, td, 8. 6,

2.6HZ) , 6.97 (IH, dd, 8.6, 2. 6Hz) , 7.03 (IH, dd, 8. 6 , 5.1Hz) , 7.60 (IH, S) , 11.37 (IH, s) .

EXAMPLE 7 7-Trifluoromethyl-3-methyl-2H-pyrimidor4.5-b"}-

[1.4]benzothiazine-2.4(3H)-dione Employing the procedure of Example 1, parts A, B and C, with 3-methylpyrimidine-2,4(IH,3H)-dione and 2-amino-4- trifluoro ethylbenzenethiol yielded the title compound. m.p.: 238°C

IR: (KBr)cπf¹: 1730, 1670, 1585, 1555, 1535, 1340, 1310, 1290, 1210, 1175, 1120, 945

NMR: (DMSO-dg) δ 8.48 (IH, s) , 8.25 (IH, m) , 8.16 (IH, m), 3.27 (3H, s) . EXAMPLE 8

3.8-Dimethyl-2H-pyrimido[4.5-bl- [1.41benzothiazine-2_r4f3H)-dione Employing the procedure of Example 1, parts A, B and C, with 3-methylpyrimidine-2,4(lH,3H)-dione and 2-amino-5- ethoxybenzenethiol yielded the title compound, m.p.: 250°C (dec.)

IR: (KBr)cm'¹: 1700, 1665, 1515, 1440, 1115 NMR: (DMSO-dg) fi: 8.07 (IH, d, 8Hz) , 7.83 (IH, s) , 7.59 (IH, d, 8Hz) , 3.25 (3H, s) , 2.07 (3H, s) . EXAMPLE 9

8-Ethoxy-3-methyl-2H-Pyrimidof4.5-b - [1.41benzothiazine-2_r4(3H.-dione Employing the procedure of Example 1, parts A, B and C, with 3-methylpyrimidine-2,4(IH,3H)-dione and 2-amino-5- ethoxybenzenethiol yielded the title compound, m.p.: 280°C (dec.) IR: (KBr)cπf¹: 1700, 1660, 1520, 1235

NMR: (DMSO-dg) δ : 8.11 (IH, d, 8Hz) , 7.65 (IH, s) , 7.34 (IH, d, 8HZ), 4.26 (2H, q, 7Hz) , 3.24 (3H, s) , 1.40 (3H, t, 7HZ) . EXAMPLE 10 8-Chloro-l.5-dihvdro-3-methyl-2H-pyrimido- r4.5-bl r1.41benzothiazine-2.4 (3H_-dione Employing the procedure of Example 1, parts A and B, with 3-methylpyrimidine-2,4(1H,3H)-dione and 2-amino-5- chlorobenzenethiol yielded the title compound, m.p.: 288.3°C

IR: (KBr)cπr¹: 3275, 3200, 3104, 1718, 1694, 1600, 1471, 1305, 813, 742 NMR: (DMSO-dg) δ : 3.13 (3H, s) , 6.97-7.05 (2H, m) , 7.08 (IH, d, 2.2Hz), 7.77 (IH, s) , 11.38 (IH, s) .

EXAMPLE 11 1.5-Dihydro-3.7.8-trimethyl-2H-pyrimido[4.5-b-)- r1.41benzothiazine-2.4(3H)-dione Employing the procedure of Example 1, parts A and B, with 3-methylpyrimidine-2,4(1H,3H)-dione and 2-amino-4,5- dimethylbenzenethiol yielded the title compound, m.p.: >300^βC

IR: (KBr)cm¹: 3340, 1698, 1621, 1300, 903, 753 NMR: (DMSO-dg) δ : 2.04 (6H, s) , 3.13 (3H, s) , 6.71 (IH, s) , 6.81 (IH, S) , 7.26 (IH, s) , 11.29 (IH, s) .

EXAMPLE 12 1.5-Dihydro-l-methoxyethyl-3-methyl-2H-pyrimido- f4.5-bl r1.4 benzothiazine-2.4 (3H)-dione Employing the procedure of Example 1, parts A and B, with l-methoxyethyl-3-methylpyrimidine-2,4(lH,3H)-dione and 2-aminobenzenethiol yielded the title compound, m.p.: 130°C

IR: (KBr)cm-¹: 3330, 1685, 1620, 1585, 1445, 1120, 750 NMR: (DMSO-dg) δ : 7.81 (IH, s) , 7.03-7.14 (3H, m) , 6.82 (IH, dt, 1.5Hz, 7.3Hz), 4.05 (2H, t, 5.5Hz), 3.54 (2H, t, 5.5Hz), 3.27 (3H, s) , 3.21 (3H, S) . EXAMPLE 13 1.5-Dihydro-3-propyl-2H-pyrimidof4.5-bl~ f1.41benzothiazine-2,4(3H)-dione Employing the procedure of Example 1, parts A and B, with 3-n-propylpyrimidine-2,4(lH,3H)-dione and 2-amino- benzenethiol yielded the title compound, m.p.: 287^βC

IRMKBrJCBf¹: 3255, 1695, 1605, 1575, 1305, 1260, 930 NMR: (CDC1₃) δ : 11.33 (IH, s) , 7.54 (IH, s) , 6.93- 7.00 (3H, m) , 6.76 (IH, m) , 3.73 (2H, t, 7.3Hz) , 1.53 (2H, ) , 0.84 (3H, t, 7.3Hz).

EXAMPLE 14 3-Butyl-l.5-dihydro-2H-pyrimido[4.5-bl~ r1.41benzothiazine-2.4(3H)-dione Employing the procedure of Example 1, parts A and B, with 3-butylpyrimidine-2,4(lH,3H)-dione and 2-aminobenzene- thiol yielded the title compound, m.p.: 277-278^βC (dec.)

IR: (KBr)cm^*1: 3300, 3100, 2960, 1712, 1603, 1465, 1306, 1260, 753, 740

NMR: (DMSO-dg) δ : 0.89 (3H, t, 7.3Hz), 1.27 (2H, qt, 7.3, 7.2Hz), 1.50 (2H, tt, 7.3, 7.2Hz), 3.77 (2H, t, 7.3HZ), 6.72-6.77 (IH, m) , 6.94 (IH, d, 7.3Hz) , 6.97-7.00 (2H, m), 7.54 (IH, s) , 11.33 (IH, s). EXAMPLE 15

1 _r5-Dihydro-l-isopropyl-3-methyl-2H-pyrimido- [4 _r5-bl f1_. ⁴ benzothiazine-2.4f3H)-dione Employing the procedure of Example 1, parts A and B, with l-isopropyl-3-methylpyrimidine-2,4(lH,3H)-dione and 2- aminobenzenethiol yielded the title compound, m.p.: 167°C

IR:(KBr)cm-^χ: 3330, 3280, 1690, 1630, 1455, 745 NMR: (CDCI₃) δ: 7.09 (IH, dt, 1.5Hz, 8Hz) , 7.01 (IH, d, 8Hz), 6.87 (IH, dt, 1.5Hz, 8Hz) , 6.72 (IH, dd, 1.5Hz, 8HZ), 6.26 (IH, s) , 4.85 (IH, sev, 7Hz) , 3.34 (3H, s) , 1.58 (6H, d, 7Hz) . EXAMPLE 16 7-Trifluoromethyl-1.5-dihvdro-3-methyl-2H-pyrimido- [4.5-bl [1.41benzothiazine-2.4.3H_ -dione Employing the procedure of Example 1, parts A and B, with 3-methylpyrimidine-2,4(lH,3H)-dione and 2-amino-4- trifluoromethylbenzenethiol yielded the title compound, m.p.: >300^βC

IR: (KBr)cm¹: 3350, 1710, 1610, 1330, 1120, 940, 750 NMR: (DMSO-dg) δ : 11.45 (IH, s) , 7.97 (IH, d, 1.8Hz), 7.14 (IH, d, 8Hz) , 7.01 (IH, dd, 8Hz, 1.8Hz).

EXAMPLE 17 7-Trifluoromethyl-1.5-dihydro-3-propyl-2H-pyrimido[4.5- b] [1.41benzothiazine-2.4.3H.-dione » Hydrobromide

Employing the procedure of Example 1, parts A and B, with 3-n-propylpyrimidine-2,4(lH,3H)-dione and 2-amino-4- trifluoromethylbenzenethiol yielded the title compound, m.p. : >300°C

IR: (KBr)cm¹: 3280, 1710, 1610, 1460, 1330, 1120 NMR: (DMSO-dg) δ : 11.43 (IH, s) , 7.96 (IH, s) , 7.34 (IH, s), 7.17 (IH, d, 8Hz) , 7.03 (IH, d, 8Hz) , 3.73 (2H, t, 7.3Hz), 1.53 (2H, m) , 0.85 (3H, t, 7.3Hz) .

EXAMPLE 18 3-Butyl-7-trifluoromethyl-1.5-dihydro-2H-pyrimido- [4.5-bl [1.41benzothiazine-2.4.3H.-dione Employing the procedure of Example 1, parts A and B, with 3-butylpyrimidine-2,4(1H,3H)-dione and 2-amino-4- trifluoromethylbenzenethiol yielded the title compound, m.p.: >300°C

IR: (KBr)cm-¹: 3250, 2975, 1710, 1610, 1460, 1330, 950, 750

NMR: (DMSO-dg) δ : 0.89 (2H, t, 7.3Hz), 1.27 (2H, qt, 7.3, 7.3Hz), 1.50 (2H, tt, 7.3, 7.1Hz), 3.76 (2H, t, 7.1Hz), 7.02 (IH, dd, 8.1, 1.5Hz), 7.15 (IH, d, 8.1Hz), 7.34 (IH, d, 1.5Hz), 7.95 (IH, s) , 11.4 (IH, s) . EXAMPLE 19 1-Cyclopentyl-l.5-dihvdro-3-methyl-2H-pyrimido- [4.5-bl r1.41benzothiazine-2.4f3H )-dione Employing the procedure of Example 1, parts A and B, with l-cyclopentyl-3-methylpyrimidine-2,4(lH,3H)-dione and 2-aminobenzenethiol yielded the title compound, m.p. : 166^βC

IR: (KBr)cnf¹: 3400, 1690, 1630, 1480, 1340, 1300, 1180

NMR: (CDC1₃) δ: 7.08 (IH, dt, 1.5Hz, 7.5Hz) , 7.01 (IH, dd, 1.5Hz, 7.5Hz), 6.87 (IH, dt, 1.5Hz, 7.5Hz), 6.71

(IH, dd, 1.5Hz, 7.5Hz), 6.25 (IH, s) , 4.75 (IH, s) , 3.35

(3H, s) , 2.21 (2H, m), 1.95 (4H, m) , 1.60 (2H, m) .

EXAMPLE 20 1-Benzyl-l.5-dihvdro-3-methyl-2H-pyrimido[4.5-b]- [l_r benzothiazine-2_f4(3H_-dione

Employing the procedure of Example 1, parts A and B, with l-benzyl-3-methylpyrimidine-2,4(lH,3H)-dione and 2- aminobenzenethiol yielded the title compound, m.p.: 193^βC IR: (KBr)cm¹: 3320, 1685, 1625, 1580, 1460, 740

NMR: (DMSO-dg) δi 7.88 (IH, s) , 7.28-7.37 (5H, m) , 7.08 (IH, m) , 7.06 (IH, m) , 6.94 (IH, m) , 6.81 (IH, m) , 5.14 (2H, s) , 3.25 (3H, s) .

EXAMPLE 21 6-Chloro-3-methyl-2H-pyrimido[4.5-bl~

[1_f41benzothiazine-2.4.3H)-dione Employing the procedure of Example 1, parts A, B and C, with 3-methylρyrimidine-2,4(lH,3H)-dione and 2-amino-3- chlorobenzenethiol yielded the title compound. m.p.: 271-273°C (dec.)

IR: (KBr)cm : 1716, 1662, 1527, 1130, 787, 742

NMR: (DMSO-dg) δl 3.16 (3H, s) , 7.60-7.78 (3H, m) . EXAMPfrE ?2 8-Fluoro-3-methyl-2H-pyrimidθ-4.5-bl- r1.41benzothiazine-2.4 (3H.-dione Employing the procedure of Example 1, parts A, B and C, with 3-methylpyrimidine-2,4(lH,3H)-dione and 2-amino-5- fluorobenzenethiol yielded the title compound, m.p.: >300°C

IR: (KBr)cm'¹: 1571, 1518, 1293, 1278, 1230, 1216, 1138, 1118 NMR: (DMSO-dg) δ : 3.25 (3H, s) , 7.63 (IH, td, 8.8, 2.9Hz), 8.05 (IH, dd, 8.8, 2.9Hz), 8.26 (IH, dd, 5.7, 8.8Hz) .

EXAMPLE 23 8-Methoxy-3-methyl-2H-pyrimido_4.5-bl- r1.41benzothiazine-2.4 (3H_-dione

Employing the procedure of Example 1, parts A, B and C, with 3-methylpyrimidine-2,4(lH,3H)-dione and 2-amino-5- methoxybenzenethiol yielded the title compound, m.p.: 258.5°C IR: (KBr)cm¹: 1700, 1654, 1511, 1339, 1233, 1118

NMR: (DMSO-dg) δ : 3.24 (3H, S) , 3.97 (3H, s) , 7.35 (IH, dd, 8.8, 2.9Hz), 7.67 (IH, d, 2.9Hz), 8.11 (IH, d, 8.8HZ) .

EXAMPLE 24 3.7.8-Trimethyl-2H-pyrimidor4.5-bl-

[1.41benzothiazine-2.4.3H_-dione Employing the procedure of Example 1, parts A, B and C, with 3-methylpyrimidine-2,4(1H,3H)-dione and 2-amino-4,5- dimethylbenzenethiol yielded the title compound. m.p.: >300°C

IR: (KBr)cm-¹: 1703, 1680, 1522, 1237, 1128 NMR: (DMSO-dg) δ i 2.40 (3H, s) , 2.42 (3H, s) , 3.25 (3H, s) , 7.81 (IH, s), 8.01 (IH, s) . EXAMPLE 25 3-Butyl-2H-pyrimido[ .5-bl[1.41benzothiazine-2,4.3H.-dione Employing the procedure of Example 1, parts A, B and C, with 3-butylpyrimidine-2,4(lH,3H)-dione and 2-aminobenzene- thiol yielded the title compound, m.p.: 250-251°C IR: (KBr)cπf¹: 1717, 1650, 1518, 1428, 780

Claims

CLAIMS 1. A compound of formula

(I) (II)

and the pharmaceutically-acceptable salts thereof, wherein R¹ is hydrogen or (Cj-C₆)alkyl; R² is hydrogen, halogen,

(C,-C₆)alkyl, (Cj-Cg)alkoxy or

alkyl; R³ is hydrogen or (Cι-C₆)alkyl; R⁴ is hydrogen, (C_j-C₆)alkyl, (C₃- Cg)cycloalkyl, (Cj-Cg)alkoxy-(Cj-C₆)alkyl or aryl-(Cj-C₆)alkyl; provided that in formula (I), R¹, R², R³ and R⁴ are not simultaneously hydrogen, R², R³ and R⁴ are not simultaneously hydrogen when R¹ is methyl and R² and R³ are not simultaneous¬ ly hydrogen when R¹ and R⁴ are respectively methyl; provided further that in formula (II) , R¹, R² and R³ are not simulta¬ neously hydrogen and R² and R³ are not simultaneously hydrogen when R¹ is methyl; and provided further still that the groups R² and R³ may be attached to any available position on the ring in formula (I) or (II) .

2. A compound according to claim 1 of the formula

(I) or a pharmaceutically-acceptable salt thereof wherein R¹, R², R³ and R⁴ are as defined in claim 1.

3. A compound according to claim 1 of the formula

( I I ) or a pharmaceutically-acceptable salt thereof wherein R¹, R², R³ and R⁴ are as defined in claim 1.

4. A compound or a pharmaceutically-acceptable salt thereof according to claim 2 wherein R¹ is (C^Cg)alkyl.

5. A compound or a pharmaceutically-acceptable salt thereof according to claim 4 wherein R¹ is methyl.

6. A compound or a pharmaceutically-acceptable salt thereof according to claim 5 wherein R² is halogen.

7. A compound or a pharmaceutically-acceptable salt thereof according to claim 5 wherein R² is (Ci-C)alkyl.

8. A compound or a pharmaceutically-acceptable salt thereof according to claim 5 wherein R² is (Cj-Cg)alkoxy.

9. A compound or a pharmaceutically-acceptable salt thereof according to claim 3 wherein R¹ is (C_t-C)alkyl.

10. A compound or a pharmaceutically-acceptable salt thereof according to claim 9 wherein R¹ is methyl.

11. A compound or a pharmaceutically-acceptable salt thereof according to claim 10 wherein R² is halogen.

12. A compound or a pharmaceutically-acceptable salt thereof according to claim 10 wherein R² is

13. A compound or a pharmaceutically-acceptable salt thereof according to claim 10 wherein R² is (Cj-Cg)alkoxy.

14. A compound or a pharmaceutically-acceptable salt thereof according to claim 10 wherein R² is (C_j-Cg)halo- substituted alkyl.

15. A pharmaceutical composition for the treatment of an allergic condition, inflammatory condition or cardiovas- cular disease in a mammal which comprises an effective amount of a compound according to claim 1 or a pharmaceuti- cally-acceptable salt thereof and a pharmaceutically- acceptable diluent or carrier.

16. A method for treating an allergic condition in a mammal which comprises administering to said mammal an effective amount of a compound according to claim 1 or a pharmaceutically-acceptable salt thereof.

17. A method for treating an inflammatory condition in a mammal which comprises administering to said mammal an effective amount of a compound according to claim 1 or a pharmaceutically-acceptable salts thereof.

18. A method for treating a cardiovascular disease in a mammal which comprises administering to said mammal an effective amount of a compound according to claim 1 or a pharmaceutically-acceptable salt thereof.

19. A process for preparing a compound of the formula

(I) (II)

and the pharmaceutically-acceptable salts thereof, wherein R¹ is hydrogen or (Cj-C₆)alkyl; R² is hydrogen, halogen, (C,-C₆)alkyl, (C,-C₆)alkoxy or (C,-C₆)halosubstituted alkyl; R³ is hydrogen or (Cj-Cg)alkyl; R⁴ is hydrogen, (C_j-C₆)alkyl, (C₃- C₈)cycloalkyl, (Cj-Cg)alkoxy-(C,-C₆)alkyl or aryl-(Cj-C₆)alkyl; provided that in formula (I) , R¹, R², R³ and R⁴ are not simultaneously hydrogen, R², R³ and R⁴ are not simultaneously hydrogen when R¹ is methyl and R² and R³ are not simulta- neously hydrogen when R¹ and R⁴ are respectively methyl; provided further that in formula (II), R¹, R² and R³ are not simultaneously hydrogen and R² and R³ are not simultaneously hydrogen when R¹ is methyl; and provided further still that the groups R² and R³ may be attached to any available position on the ring in formula (I) or (II) , which comprises reacting a compound of the formula

(IV)

wherein R¹ and R⁴ are as defined above, with N-bromosuccin- imide and reacting the product thereof with a compound of the formula

(V)

wherein R² and R³ are as defined above, at reflux to yield a compound of formula (I) ; and when a compound of formula (II) is desired, reacting a corresponding compound of formula (I) wherein R⁴ is hydrogen with an oxidant to yield a compound of formula (II) ; and when a pharmaceutically-acceptable salt of a compound of formula (I) or formula (II) is desired, converting the compound of formula (I) or formula (II) to the pharmaceutically-acceptable salt thereof by methods known per se.

20. A process according to claim 19 wherein a compound of formula (I) or a pharmaceutically-acceptable salt is prepared.

21. A process according to claim 19 wherein a compound of formula (II) or a pharmaceutically-acceptable salt thereof is prepared.